The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120

  • Nicos Karasavvas
  • , Erik Billings
  • , Mangala Rao
  • , Constance Williams
  • , Susan Zolla-Pazner
  • , Robert T. Bailer
  • , Richard A. Koup
  • , Sirinan Madnote
  • , Duangnapa Arworn
  • , Xiaoying Shen
  • , Georgia D. Tomaras
  • , Jeffrey R. Currier
  • , Mike Jiang
  • , Craig Magaret
  • , Charla Andrews
  • , Raphael Gottardo
  • , Peter Gilbert
  • , Timothy J. Cardozo
  • , Supachai Rerks-Ngarm
  • , Sorachai Nitayaphan
    • Punnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil, Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, Mark S. De Souza

Research output: Contribution to journal › Article › peer-review

181 Scopus citations

Fingerprint

Dive into the research topics of 'The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology